サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1508688

膀胱がん治療薬市場：世界の産業分析、規模、シェア、成長、動向、予測、2024年～2033年

Bladder Cancer Treatment Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

出版日
ページ情報
英文 189 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
膀胱がん治療薬市場：世界の産業分析、規模、シェア、成長、動向、予測、2024年～2033年
出版日: 2024年07月03日
発行: Persistence Market Research
ページ情報: 英文 189 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Researchはこのほど、膀胱がん治療薬市場に関する包括的なレポートを発表しました。当レポートでは、市場促進要因・動向・機会・課題を含む重要な市場ダイナミクスを徹底的に評価し、市場構造に関する詳細な洞察を提供しています。

主要な洞察

  • 膀胱がん治療薬の市場規模（2024年）：38億米ドル
  • 予測市場金額（2033年）：148億米ドル
  • 世界市場成長率（CAGR 2024年～2033年）：16.3%

膀胱がん治療薬市場 - レポート範囲：

膀胱がん治療薬は、非筋肉浸潤性膀胱がん（NMIBC）や筋浸潤性膀胱がん（MIBC）を含む様々な段階の膀胱がんの管理と治療に重要な役割を果たしています。これらの薬剤は、特定の経路や細胞メカニズムを標的として、がんの増殖を抑制し、生存率を向上させ、患者の生活の質を高めます。同市場は、病院、腫瘍センター、外来診療所を対象としており、化学療法剤、免疫療法剤、標的治療薬など、さまざまな種類の薬剤を提供しています。

市場成長の促進要因：

世界の膀胱がん治療薬市場は、世界の膀胱がん罹患率の増加、膀胱がんに関連する特定の遺伝子変異やバイオマーカーを標的とした薬剤開発の進展、治療成績向上のための併用療法の採用拡大など、いくつかの主要な要因によって促進されています。さらに、ヘルスケア支出の増加、がんの早期発見に関する患者の意識の拡大、がん研究に対する政府の支援策が市場拡大に寄与しています。

市場抑制要因：

有望な成長が見込まれるものの、膀胱がん治療薬市場は、新薬開拓に伴う高コスト、医薬品承認に向けた厳しい規制要件、化学療法や免疫療法に伴う潜在的な副作用などの課題に直面しています。特定の治療法に対する償還範囲が限定的であることや、個別化治療アプローチの必要性が、特に新興国において市場浸透のさらなる課題となっています。

市場機会：

膀胱がん治療薬市場は、現在進行中の新薬候補の臨床試験、創薬を加速するための製薬企業と研究機関の戦略的提携、個別化がん治療のための精密医療アプローチの進歩などにより、大きな成長機会をもたらしています。さらに、バイオマーカー主導型診断とコンパニオン診断の統合は、治療効果と患者の転帰を向上させ、市場の成長を促進します。

本レポートで扱う主要な質問

  • 膀胱がん治療薬市場の世界的成長を促進する主要な要因は何か？
  • さまざまなヘルスケア環境において、どのような薬剤の種類と治療方法が採用を促進しているか？
  • 技術の進歩とバイオマーカー主導型診断は、膀胱がん治療薬市場の競合情勢をどのように変えているのか？
  • 膀胱がん治療薬市場に貢献している主要企業はどこで、市場の関連性を維持するためにどのような戦略を採用しているのか？
  • 世界の膀胱がん治療薬市場における新たな動向と将来展望は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲 / 分類
  • 市場の定義 / 範囲 / 制限

第3章 主要な市場動向

  • 市場に影響を与える主要な動向

第4章 主要な成功要因

  • 製品採用分析
  • 主要戦略：メーカー別
  • 規制シナリオ
  • ポーター分析
  • PESTLE分析
  • サプライチェーン分析
  • 研究開発への資金提供
  • 臨床試験分析
  • パイプライン分析
  • 地域別の疾病疫学
  • 払い戻しシナリオ
  • 親市場分析

第5章 市場背景

  • マクロ経済要因
  • 予測要因 - 関連性と影響
  • 市場力学

第6章 COVID-19危機 - 影響評価

    • COVID-19の影響 - 2024年の市場シナリオ
    • COVID-19の影響概要

第7章 世界市場の需要（金額または規模、10億米ドル）分析

  • 過去の市場金額（10億米ドル）の分析、2019年～2023年
  • 現在および将来の市場金額（10億米ドル）予測、2024年～2033年
    • 前年比成長動向分析
    • 絶対額の機会分析

第8章 世界市場分析：膀胱がんタイプ別

  • イントロダクション / 主要な調査結果
  • 過去の市場規模（10億米ドル）の分析：膀胱がんタイプ別、2019年～2023年
  • 現在および将来の市場規模（10億米ドル）の分析と予測：膀胱がんタイプ別、2024年～2033年
    • 非筋層浸潤性膀胱がん
    • 筋層浸潤性膀胱がん
  • 市場の魅力分析：膀胱がんタイプ

第9章 世界市場分析：がんのグレード別

  • イントロダクション / 主要な調査結果
  • 過去の市場規模（10億米ドル）の分析：がんのグレード別、2019年～2023年
  • 現在および将来の市場規模（10億米ドル）の分析と予測：がんのグレード別、2024年～2033年
    • 低悪性度膀胱がん
    • 高悪性度膀胱がん
  • 市場の魅力分析：がんのグレード別

第10章 世界市場分析：医薬品タイプ別

  • イントロダクション / 主要な調査結果
  • 過去の市場規模（10億米ドル）の分析：医薬品タイプ別、2019年～2023年
  • 現在および将来の市場規模（10億米ドル）の分析と予測：医薬品タイプ別、2024年～2033年
    • 免疫療法
    • 化学療法
    • 標的療法
  • 市場の魅力分析：医薬品タイプ別

第11章 世界市場分析：流通チャネル別

  • イントロダクション / 主要な調査結果
  • 過去の市場規模（10億米ドル）の分析：流通チャネル別、2019年～2023年
  • 現在および将来の市場規模（10億米ドル）の分析と予測：流通チャネル別、2024年～2033年
    • 病院薬局
    • 小売薬局
    • 専門薬局
    • オンライン薬局
  • 市場の魅力分析：流通チャネル別

第12章 世界市場分析：地域別

  • イントロダクション
  • 過去の市場規模（10億米ドル）の分析：地域別、2019年～2023年
  • 現在の市場規模（10億米ドル）の分析と予測：地域別、2024年～2033年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東・アフリカ（MEA）
  • 市場の魅力分析：地域別

第13章 北米市場分析

第14章 ラテンアメリカ市場分析

第15章 欧州市場分析

第16章 南アジア市場分析

第17章 東アジア市場分析

第18章 オセアニア市場

第19章 中東・アフリカ（MEA）市場分析

第20章 市場構造分析

  • 市場分析：企業階層別
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第21章 競合分析

  • 競合ダッシュボード
  • 競合ベンチマーク
  • 競合の詳細情報[暫定リスト]
    • Pfizer Inc.
    • Merck KGaA
    • Merck &Co
    • AstraZeneca PLC
    • Roche Holding AG（Genentech）
    • Astellas Pharma Inc.
    • J&J（Janssen Biotech）
    • Cipla Inc.
    • Amneal Pharma
    • Bristol Myers Squibb Co.
    • Dr. Reddy's Laboratories, Inc.
    • Gilead Sciences Inc.
    • Endo Pharma
    • UroGen Pharma, Inc.
    • Teva Pharmaceuticals（Actavis）
    • Hikma Pharmaceuticals
    • Incyte

第22章 使用される前提条件と頭字語

第23章 調査手法

目次
Product Code: PMRREP4465

Persistence Market Research has recently released a comprehensive report on the "Bladder Cancer Treatment Drugs Market." The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

  • Bladder Cancer Treatment Drugs Market Size (2024E): USD 3.8 Billion
  • Projected Market Value (2033F): USD 14.8 Billion
  • Global Market Growth Rate (CAGR 2024 to 2033): 16.3%

Bladder Cancer Treatment Drugs Market - Report Scope:

Bladder cancer treatment drugs play a critical role in managing and treating various stages of bladder cancer, including non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). These drugs target specific pathways and cellular mechanisms to inhibit cancer growth, improve survival rates, and enhance quality of life for patients. The market caters to hospitals, oncology centers, and outpatient clinics, offering a range of drug types, including chemotherapy agents, immunotherapy drugs, and targeted therapies.

Market Growth Drivers:

The global bladder cancer treatment drugs market is driven by several key factors, including the increasing incidence of bladder cancer globally, advancements in drug development targeting specific genetic mutations and biomarkers associated with bladder cancer, and growing adoption of combination therapies to improve treatment outcomes. Additionally, rising healthcare expenditures, expanding patient awareness about early cancer detection, and supportive government initiatives for cancer research contribute to market expansion.

Market Restraints:

Despite promising growth prospects, the bladder cancer treatment drugs market faces challenges such as high costs associated with novel drug development, stringent regulatory requirements for drug approval, and potential adverse effects associated with chemotherapy and immunotherapy treatments. Limited reimbursement coverage for certain therapies and the need for personalized treatment approaches further pose challenges for market penetration, particularly in emerging economies.

Market Opportunities:

The bladder cancer treatment drugs market presents significant growth opportunities driven by ongoing clinical trials for novel drug candidates, strategic collaborations between pharmaceutical companies and research institutions to accelerate drug discovery, and advancements in precision medicine approaches for personalized cancer therapy. Furthermore, the integration of biomarker-driven diagnostics and companion diagnostics enhances treatment efficacy and patient outcomes, fostering market growth.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the bladder cancer treatment drugs market globally?
  • Which drug types and treatment modalities are driving adoption across different healthcare settings?
  • How are technological advancements and biomarker-driven diagnostics reshaping the competitive landscape of the bladder cancer treatment drugs market?
  • Who are the key players contributing to the bladder cancer treatment drugs market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global bladder cancer treatment drugs market?

Competitive Intelligence and Business Strategy:

Leading players in the global bladder cancer treatment drugs market, including Pfizer Inc.,Merck KgaA,Cipla Inc., focus on innovation, clinical research, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop targeted therapies, immune checkpoint inhibitors, and combination treatments that improve patient outcomes and extend survival rates. Collaborations with oncology centers, patient advocacy groups, and regulatory agencies facilitate drug approval and market access, supporting advancements in bladder cancer treatment.

Key Companies Profiled:

  • Pfizer Inc.
  • Merck KgaA
  • Merck & Co
  • AstraZeneca PLC
  • Roche Holding AG (Genentech)
  • Astellas Pharma Inc.
  • J&J (Janssen Biotech)
  • Cipla Inc.
  • Amneal Pharma,
  • Bristol Myers Squibb Co.
  • Dr Reddy's Laboratories, Inc.
  • Gilead Sciences Inc.
  • Endo Pharma
  • UroGen Pharma, Inc.
  • Teva Pharmaceuticals (Actavis)
  • Hikma Pharmaceuticals, Incyte

Market Segmentation

By Cancer Type

  • Non-Muscle-Invasive Bladder Cancer
  • Muscle-Invasive Bladder Cancer

By Cancer Grade

  • Low-Grade Bladder Cancer
  • High-Grade Bladder Cancer

By Drug Type

  • Immunotherapy
  • Chemotherapy
  • Targeted Therapy

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Specialty Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market

4. Key Success Factors

  • 4.1. Product Adoption Analysis
  • 4.2. Key Strategies, by Manufacturers
  • 4.3. Regulatory Scenario
  • 4.4. Porters Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Supply Chain Analysis
  • 4.7. Funding In Research & Development
  • 4.8. Clinical Trials Analysis
  • 4.9. Pipeline Analysis
  • 4.10. Disease Epidemiology, by Region
  • 4.11. Reimbursement Scenario
  • 4.12. Parent Market Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Pharmaceutical Industry Overview
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Rising Healthcare Spending
    • 5.2.2. Increasing Prevalence of Cancer
    • 5.2.3. Increasing Awareness and Supportive Government Initiatives
    • 5.2.4. Increase in Funding for
    • 5.2.5. Cancer Research
    • 5.2.6. Increase In Product Launches
    • 5.2.7. Strong Product Pipeline
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis - Impact Assessment

    • 6.1.1. Impact of COVID-19 - 2024 Market Scenario
    • 6.1.2. COVID-19 Impact Summary

7. Global Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

  • 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Bladder Cancer Type

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Bn) Analysis by Bladder Cancer Type, 2019-2023
  • 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast by Bladder Cancer Type, 2024-2033
    • 8.3.1. Non-Muscle-Invasive Bladder Cancer
    • 8.3.2. Muscle-Invasive Bladder Cancer
  • 8.4. Market Attractiveness Analysis by Bladder Cancer Type

9. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Cancer grade

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Bn) Analysis by Cancer grade, 2019-2023
  • 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast by Cancer grade, 2024-2033
    • 9.3.1. Low-grade bladder cancer
    • 9.3.2. High-grade bladder cancer
  • 9.4. Market Attractiveness Analysis by Cancer grade

10. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Drug Type

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Bn) Analysis by Drug Type, 2019-2023
  • 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast by Drug Type, 2024-2033
    • 10.3.1. Immunotherapy
      • 10.3.1.1. Bacillus Calmette-Guerin
      • 10.3.1.2. Avelumab
      • 10.3.1.3. Nivolumab
      • 10.3.1.4. Pembrolizumab
      • 10.3.1.5. Others
    • 10.3.2. Chemotherapy
      • 10.3.2.1. Mitomycin C
      • 10.3.2.2. Docetaxel
      • 10.3.2.3. Paclitaxel
      • 10.3.2.4. Cisplatin
      • 10.3.2.5. Others
    • 10.3.3. Targeted therapy
      • 10.3.3.1. Erdafitinib
      • 10.3.3.2. Enfortumab vedotin-ejfv
      • 10.3.3.3. Sacituzumab govitecan
      • 10.3.3.4. Others
  • 10.4. Market Attractiveness Analysis by Drug Type

11. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Distribution Channel

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Bn) Analysis By Distribution Channel, 2019-2023
  • 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2024-2033
    • 11.3.1. Hospital Pharmacy
    • 11.3.2. Retail Pharmacy
    • 11.3.3. Specialty Pharmacy
    • 11.3.4. Online Pharmacy
  • 11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Region

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
  • 12.3. Current Market Size (US$ Bn) Analysis and Forecast By Region, 2024-2033
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. East Asia
    • 12.3.5. South Asia
    • 12.3.6. Oceania
    • 12.3.7. Middle East and Africa (MEA)
  • 12.4. Market Attractiveness Analysis By Region

13. North America Market Analysis 2019-2023 and Forecast 2024-2033

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Bn) Analysis, By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Size (US$ Bn) Analysis, By Market Taxonomy 2024-2033
    • 13.3.1. By Country
      • 13.3.1.1. U.S.
      • 13.3.1.2. Canada
    • 13.3.2. By Bladder Cancer Type
    • 13.3.3. By Cancer Grade
    • 13.3.4. By Drug Type
    • 13.3.5. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Bladder Cancer Type
    • 13.4.3. By Cancer Grade
    • 13.4.4. By Drug Type
    • 13.4.5. By Distribution Channel
  • 13.5. Key Market Participants - Intensity Mapping
  • 13.6. Drivers and Restraints - Impact Analysis
  • 13.7. Country-Level Analysis & Forecast
    • 13.7.1. U.S. Market Analysis
      • 13.7.1.1. .Introduction
      • 13.7.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.7.1.2.1. By Bladder Cancer Type
        • 13.7.1.2.2. By Cancer Grade
        • 13.7.1.2.3. By Drug Type
        • 13.7.1.2.4. By Distribution Channel
    • 13.7.2. Canada Market Analysis
      • 13.7.2.1. Introduction
      • 13.7.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.7.2.2.1. By Bladder Cancer Type
        • 13.7.2.2.2. By Cancer Grade
        • 13.7.2.2.3. By Drug Type
        • 13.7.2.2.4. By Distribution Channel

14. Latin America Market Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Bn) and Trend Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Bn) Analysis, By Market Taxonomy, 2024-2033
    • 14.3.1. By Country
      • 14.3.1.1. Mexico
      • 14.3.1.2. Brazil
      • 14.3.1.3. Argentina
      • 14.3.1.4. Rest of Latin America
    • 14.3.2. By Bladder Cancer Type
    • 14.3.3. By Cancer Grade
    • 14.3.4. By Drug Type
    • 14.3.5. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Bladder Cancer Type
    • 14.4.3. By Cancer Grade
    • 14.4.4. By Drug Type
    • 14.4.5. By Distribution Channel
  • 14.5. Key Market Participants - Intensity Mapping
  • 14.6. Drivers and Restraints - Impact Analysis
  • 14.7. Country-Level Analysis & Forecast
    • 14.7.1. Mexico Market Analysis
      • 14.7.1.1. Introduction
      • 14.7.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.7.1.2.1. By Bladder Cancer Type
        • 14.7.1.2.2. By Cancer Grade
        • 14.7.1.2.3. By Drug Type
        • 14.7.1.2.4. By Distribution Channel
    • 14.7.2. Brazil Market Analysis
      • 14.7.2.1. Introduction
      • 14.7.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.7.2.2.1. By Bladder Cancer Type
        • 14.7.2.2.2. By Cancer Grade
        • 14.7.2.2.3. By Drug Type
        • 14.7.2.2.4. By Distribution Channel
    • 14.7.3. Argentina Market Analysis
      • 14.7.3.1. Introduction
      • 14.7.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.7.3.2.1. By Bladder Cancer Type
        • 14.7.3.2.2. By Cancer Grade
        • 14.7.3.2.3. By Drug Type
        • 14.7.3.2.4. By Distribution Channel

15. Europe Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Bn) Analysis, By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Size (US$ Bn) Analysis, By Market Taxonomy, 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. Germany
      • 15.3.1.2. Italy
      • 15.3.1.3. France
      • 15.3.1.4. U.K.
      • 15.3.1.5. Spain
      • 15.3.1.6. Poland
      • 15.3.1.7. Russia
      • 15.3.1.8. Rest of Europe
    • 15.3.2. By Bladder Cancer Type
    • 15.3.3. By Cancer Grade
    • 15.3.4. By Drug Type
    • 15.3.5. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Bladder Cancer Type
    • 15.4.3. By Cancer Grade
    • 15.4.4. By Drug Type
    • 15.4.5. By Distribution Channel
  • 15.5. Key Market Participants - Intensity Mapping
  • 15.6. Drivers and Restraints - Impact Analysis
  • 15.7. Country-Level Analysis & Forecast
    • 15.7.1. Germany Market Analysis
      • 15.7.1.1. Introduction
      • 15.7.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.7.1.2.1. By Bladder Cancer Type
        • 15.7.1.2.2. By Cancer Grade
        • 15.7.1.2.3. By Drug Type
        • 15.7.1.2.4. By Distribution Channel
    • 15.7.2. Italy Market Analysis
      • 15.7.2.1. Introduction
      • 15.7.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.7.2.2.1. By Bladder Cancer Type
        • 15.7.2.2.2. By Cancer Grade
        • 15.7.2.2.3. By Drug Type
        • 15.7.2.2.4. By Distribution Channel
    • 15.7.3. France Market Analysis
      • 15.7.3.1. Introduction
      • 15.7.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.7.3.2.1. By Bladder Cancer Type
        • 15.7.3.2.2. By Cancer Grade
        • 15.7.3.2.3. By Drug Type
        • 15.7.3.2.4. By Distribution Channel
    • 15.7.4. U.K. Market Analysis
      • 15.7.4.1. Introduction
      • 15.7.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.7.4.2.1. By Bladder Cancer Type
        • 15.7.4.2.2. By Cancer Grade
        • 15.7.4.2.3. By Drug Type
        • 15.7.4.2.4. By Distribution Channel
    • 15.7.5. Spain Market Analysis
      • 15.7.5.1. Introduction
      • 15.7.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.7.5.2.1. By Bladder Cancer Type
        • 15.7.5.2.2. By Cancer Grade
        • 15.7.5.2.3. By Drug Type
        • 15.7.5.2.4. By Distribution Channel
    • 15.7.6. Poland Market Analysis
      • 15.7.6.1. Introduction
      • 15.7.6.2. Market Analysis and Forecast by Market Taxonomy
        • 15.7.6.2.1. By Bladder Cancer Type
        • 15.7.6.2.2. By Cancer Grade
        • 15.7.6.2.3. By Drug Type
        • 15.7.6.2.4. By Distribution Channel
    • 15.7.7. Russia Market Analysis
      • 15.7.7.1. Introduction
      • 15.7.7.2. Market Analysis and Forecast by Market Taxonomy
        • 15.7.7.2.1. By Bladder Cancer Type
        • 15.7.7.2.2. By Cancer Grade
        • 15.7.7.2.3. By Drug Type
        • 15.7.7.2.4. By Distribution Channel

16. South Asia Market Analysis 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Bn) and Trend Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Bn) Analysis, By Market Taxonomy, 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. India
      • 16.3.1.2. Indonesia
      • 16.3.1.3. Malaysia
      • 16.3.1.4. Thailand
      • 16.3.1.5. Rest of South Asia
    • 16.3.2. By Bladder Cancer Type
    • 16.3.3. By Cancer Grade
    • 16.3.4. By Drug Type
    • 16.3.5. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Bladder Cancer Type
    • 16.4.3. By Cancer Grade
    • 16.4.4. By Drug Type
    • 16.4.5. By Distribution Channel
  • 16.5. Key Market Participants - Intensity Mapping
  • 16.6. Drivers and Restraints - Impact Analysis
  • 16.7. Country-Level Analysis & Forecast
    • 16.7.1. India Market Analysis
      • 16.7.1.1. Introduction
      • 16.7.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.7.1.2.1. By Bladder Cancer Type
        • 16.7.1.2.2. By Cancer Grade
        • 16.7.1.2.3. By Drug Type
        • 16.7.1.2.4. By Distribution Channel
    • 16.7.2. Indonesia Market Analysis
      • 16.7.2.1. Introduction
      • 16.7.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.7.2.2.1. By Bladder Cancer Type
        • 16.7.2.2.2. By Cancer Grade
        • 16.7.2.2.3. By Drug Type
        • 16.7.2.2.4. By Distribution Channel
    • 16.7.3. Malaysia Market Analysis
      • 16.7.3.1. Introduction
      • 16.7.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.7.3.2.1. By Bladder Cancer Type
        • 16.7.3.2.2. By Cancer Grade
        • 16.7.3.2.3. By Drug Type
        • 16.7.3.2.4. By Distribution Channel
    • 16.7.4. Thailand Market Analysis
      • 16.7.4.1. Introduction
      • 16.7.4.2. Market Analysis and Forecast by Market Taxonomy
        • 16.7.4.2.1. By Bladder Cancer Type
        • 16.7.4.2.2. By Cancer Grade
        • 16.7.4.2.3. By Drug Type
        • 16.7.4.2.4. By Distribution Channel

17. East Asia Market Analysis 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Bn) and Trend Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Size (US$ Bn) Analysis, By Market Taxonomy, 2024-2033
    • 17.3.1. By Country
      • 17.3.1.1. China
      • 17.3.1.2. Japan
      • 17.3.1.3. South Korea
    • 17.3.2. By Bladder Cancer Type
    • 17.3.3. By Cancer Grade
    • 17.3.4. By Drug Type
    • 17.3.5. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Bladder Cancer Type
    • 17.4.3. By Cancer Grade
    • 17.4.4. By Drug Type
    • 17.4.5. By Distribution Channel
  • 17.5. Key Market Participants - Intensity Mapping
  • 17.6. Drivers and Restraints - Impact Analysis
  • 17.7. Country-Level Analysis & Forecast
    • 17.7.1. China Market Analysis
      • 17.7.1.1. Introduction
      • 17.7.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.7.1.2.1. By Bladder Cancer Type
        • 17.7.1.2.2. By Cancer Grade
        • 17.7.1.2.3. By Drug Type
        • 17.7.1.2.4. By Distribution Channel
    • 17.7.2. Japan Market Analysis
      • 17.7.2.1. Introduction
      • 17.7.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.7.2.2.1. By Bladder Cancer Type
        • 17.7.2.2.2. By Cancer Grade
        • 17.7.2.2.3. By Drug Type
        • 17.7.2.2.4. By Distribution Channel
    • 17.7.3. South Korea Drugs Market Analysis
      • 17.7.3.1. Introduction
      • 17.7.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.7.3.2.1. By Bladder Cancer Type
        • 17.7.3.2.2. By Cancer Grade
        • 17.7.3.2.3. By Drug Type
        • 17.7.3.2.4. By Distribution Channel

18. Oceania Market 2019-2023 and Forecast 2024-2033

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Size (US$ Bn) Analysis, By Market Taxonomy, 2024-2033
    • 18.3.1. By Country
      • 18.3.1.1. Australia
      • 18.3.1.2. New Zealand
    • 18.3.2. By Bladder Cancer Type
    • 18.3.3. By Cancer Grade
    • 18.3.4. By Drug Type
    • 18.3.5. By Distribution Channel
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Bladder Cancer Type
    • 18.4.3. By Cancer Grade
    • 18.4.4. By Drug Type
    • 18.4.5. By Distribution Channel
  • 18.5. Key Market Participants - Intensity Mapping
  • 18.6. Drivers and Restraints - Impact Analysis
  • 18.7. Country-Level Analysis & Forecast
    • 18.7.1. Australia Market Analysis
      • 18.7.1.1. Introduction
      • 18.7.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.7.1.2.1. By Bladder Cancer Type
        • 18.7.1.2.2. By Cancer Grade
        • 18.7.1.2.3. By Drug Type
        • 18.7.1.2.4. By Distribution Channel
    • 18.7.2. New Zealand Market Analysis
      • 18.7.2.1. Introduction
      • 18.7.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.7.2.2.1. By Bladder Cancer Type
        • 18.7.2.2.2. By Cancer Grade
        • 18.7.2.2.3. By Drug Type
        • 18.7.2.2.4. By Distribution Channel

19. Middle East and Africa (MEA) Market Analysis 2019-2023 and Forecast 2024-2033

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Bn) and Trend Analysis By Market Taxonomy, 2019-2023
  • 19.3. Current and Future Market Size (US$ Bn) Analysis, By Market Taxonomy, 2024-2033
    • 19.3.1. By Country
      • 19.3.1.1. GCC Countries
      • 19.3.1.2. South Africa
      • 19.3.1.3. North Africa
      • 19.3.1.4. Turkiye
      • 19.3.1.5. Rest of Middle East and Africa
    • 19.3.2. By Bladder Cancer Type
    • 19.3.3. By Cancer Grade
    • 19.3.4. By Drug Type
    • 19.3.5. By Distribution Channel
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Country
    • 19.4.2. By Bladder Cancer Type
    • 19.4.3. By Cancer Grade
    • 19.4.4. By Drug Type
    • 19.4.5. By Distribution Channel
  • 19.5. Key Market Participants - Intensity Mapping
  • 19.6. Drivers and Restraints - Impact Analysis
  • 19.7. Country-Level Analysis & Forecast
    • 19.7.1. GCC Countries Market Analysis
      • 19.7.1.1. Introduction
      • 19.7.1.2. Market Analysis and Forecast by Market Taxonomy
        • 19.7.1.2.1. By Bladder Cancer Type
        • 19.7.1.2.2. By Cancer Grade
        • 19.7.1.2.3. By Drug Type
        • 19.7.1.2.4. By Distribution Channel
    • 19.7.2. South Africa Market Analysis
      • 19.7.2.1. Introduction
      • 19.7.2.2. Market Analysis and Forecast by Market Taxonomy
        • 19.7.2.2.1. By Bladder Cancer Type
        • 19.7.2.2.2. By Cancer Grade
        • 19.7.2.2.3. By Drug Type
        • 19.7.2.2.4. By Distribution Channel
    • 19.7.3. North Africa Market Analysis
      • 19.7.3.1. Introduction
      • 19.7.3.2. Market Analysis and Forecast by Market Taxonomy
        • 19.7.3.2.1. By Bladder Cancer Type
        • 19.7.3.2.2. By Cancer Grade
        • 19.7.3.2.3. By Drug Type
        • 19.7.3.2.4. By Distribution Channel
    • 19.7.4. Turkiye Market Analysis
      • 19.7.4.1. Introduction
      • 19.7.4.2. Market Analysis and Forecast by Market Taxonomy
        • 19.7.4.2.1. By Bladder Cancer Type
        • 19.7.4.2.2. By Cancer Grade
        • 19.7.4.2.3. By Drug Type
        • 19.7.4.2.4. By Distribution Channel

20. Market Structure Analysis

  • 20.1. Market Analysis by Tier of Companies
  • 20.2. Market Share Analysis of Top Players
  • 20.3. Market Presence Analysis
    • 20.3.1. By Regional footprint of Players
    • 20.3.2. Product footprint by Players
    • 20.3.3. Channel Foot Print by Players

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Competition Benchmarking
  • 21.3. Competition Deep Dive [Tentative list]
    • 21.3.1. Pfizer Inc.
      • 21.3.1.1. Overview
      • 21.3.1.2. Product Portfolio
      • 21.3.1.3. Business Segment Overview
      • 21.3.1.4. Sales Footprint
      • 21.3.1.5. SWOT Analysis
      • 21.3.1.6. Key Financials
      • 21.3.1.7. Strategy Overview
    • 21.3.2. Merck KGaA
      • 21.3.2.1. Overview
      • 21.3.2.2. Product Portfolio
      • 21.3.2.3. Business Segment Overview
      • 21.3.2.4. Sales Footprint
      • 21.3.2.5. SWOT Analysis
      • 21.3.2.6. Key Financials
      • 21.3.2.7. Strategy Overview
    • 21.3.3. Merck & Co
      • 21.3.3.1. Overview
      • 21.3.3.2. Product Portfolio
      • 21.3.3.3. Business Segment Overview
      • 21.3.3.4. Sales Footprint
      • 21.3.3.5. SWOT Analysis
      • 21.3.3.6. Key Financials
      • 21.3.3.7. Strategy Overview
    • 21.3.4. AstraZeneca PLC
      • 21.3.4.1. Overview
      • 21.3.4.2. Product Portfolio
      • 21.3.4.3. Business Segment Overview
      • 21.3.4.4. Sales Footprint
      • 21.3.4.5. SWOT Analysis
      • 21.3.4.6. Key Financials
      • 21.3.4.7. Strategy Overview
    • 21.3.5. Roche Holding AG (Genentech)
      • 21.3.5.1. Overview
      • 21.3.5.2. Product Portfolio
      • 21.3.5.3. Business Segment Overview
      • 21.3.5.4. Sales Footprint
      • 21.3.5.5. SWOT Analysis
      • 21.3.5.6. Key Financials
      • 21.3.5.7. Strategy Overview
    • 21.3.6. Astellas Pharma Inc.
      • 21.3.6.1. Overview
      • 21.3.6.2. Product Portfolio
      • 21.3.6.3. Business Segment Overview
      • 21.3.6.4. Sales Footprint
      • 21.3.6.5. SWOT Analysis
      • 21.3.6.6. Key Financials
      • 21.3.6.7. Strategy Overview
    • 21.3.7. J&J (Janssen Biotech)
      • 21.3.7.1. Overview
      • 21.3.7.2. Product Portfolio
      • 21.3.7.3. Business Segment Overview
      • 21.3.7.4. Sales Footprint
      • 21.3.7.5. SWOT Analysis
      • 21.3.7.6. Key Financials
      • 21.3.7.7. Strategy Overview
    • 21.3.8. Cipla Inc.
      • 21.3.8.1. Overview
      • 21.3.8.2. Product Portfolio
      • 21.3.8.3. Business Segment Overview
      • 21.3.8.4. Sales Footprint
      • 21.3.8.5. SWOT Analysis
      • 21.3.8.6. Key Financials
      • 21.3.8.7. Strategy Overview
    • 21.3.9. Amneal Pharma
      • 21.3.9.1. Overview
      • 21.3.9.2. Product Portfolio
      • 21.3.9.3. Business Segment Overview
      • 21.3.9.4. Sales Footprint
      • 21.3.9.5. SWOT Analysis
      • 21.3.9.6. Key Financials
      • 21.3.9.7. Strategy Overview
    • 21.3.10. Bristol Myers Squibb Co.
      • 21.3.10.1. Overview
      • 21.3.10.2. Product Portfolio
      • 21.3.10.3. Business Segment Overview
      • 21.3.10.4. Sales Footprint
      • 21.3.10.5. SWOT Analysis
      • 21.3.10.6. Key Financials
      • 21.3.10.7. Strategy Overview
    • 21.3.11. Dr. Reddy's Laboratories, Inc.
      • 21.3.11.1. Overview
      • 21.3.11.2. Product Portfolio
      • 21.3.11.3. Business Segment Overview
      • 21.3.11.4. Sales Footprint
      • 21.3.11.5. SWOT Analysis
      • 21.3.11.6. Key Financials
      • 21.3.11.7. Strategy Overview
    • 21.3.12. Gilead Sciences Inc.
      • 21.3.12.1. Overview
      • 21.3.12.2. Product Portfolio
      • 21.3.12.3. Business Segment Overview
      • 21.3.12.4. Sales Footprint
      • 21.3.12.5. SWOT Analysis
      • 21.3.12.6. Key Financials
      • 21.3.12.7. Strategy Overview
    • 21.3.13. Endo Pharma
      • 21.3.13.1. Overview
      • 21.3.13.2. Product Portfolio
      • 21.3.13.3. Business Segment Overview
      • 21.3.13.4. Sales Footprint
      • 21.3.13.5. SWOT Analysis
      • 21.3.13.6. Key Financials
      • 21.3.13.7. Strategy Overview
    • 21.3.14. UroGen Pharma, Inc.
      • 21.3.14.1. Overview
      • 21.3.14.2. Product Portfolio
      • 21.3.14.3. Business Segment Overview
      • 21.3.14.4. Sales Footprint
      • 21.3.14.5. SWOT Analysis
      • 21.3.14.6. Key Financials
      • 21.3.14.7. Strategy Overview
    • 21.3.15. Teva Pharmaceuticals (Actavis)
      • 21.3.15.1. Overview
      • 21.3.15.2. Product Portfolio
      • 21.3.15.3. Business Segment Overview
      • 21.3.15.4. Sales Footprint
      • 21.3.15.5. SWOT Analysis
      • 21.3.15.6. Key Financials
      • 21.3.15.7. Strategy Overview
    • 21.3.16. Hikma Pharmaceuticals
      • 21.3.16.1. Overview
      • 21.3.16.2. Product Portfolio
      • 21.3.16.3. Business Segment Overview
      • 21.3.16.4. Sales Footprint
      • 21.3.16.5. SWOT Analysis
      • 21.3.16.6. Key Financials
      • 21.3.16.7. Strategy Overview
    • 21.3.17. Incyte
      • 21.3.17.1. Overview
      • 21.3.17.2. Product Portfolio
      • 21.3.17.3. Business Segment Overview
      • 21.3.17.4. Sales Footprint
      • 21.3.17.5. SWOT Analysis
      • 21.3.17.6. Key Financials
      • 21.3.17.7. Strategy Overview

22. Assumptions and Acronyms Used

23. Research Methodology